Zumla, A;
Rao, M;
Dodoo, E;
Maeurer, M;
(2016)
Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis.
BMC Medicine
, 14
, Article 89. 10.1186/s12916-016-0635-1.
Preview |
Text
Zumla_#Zumla, Rao, Dodo, MAeurer.pdf - Published Version Download (1MB) | Preview |
Abstract
Treatment of multidrug-resistant tuberculosis (MDR-TB) is extremely challenging due to the virulence of the etiologic strains of Mycobacterium tuberculosis (M. tb), the aberrant host immune responses and the diminishing treatment options with TB drugs. New treatment regimens incorporating therapeutics targeting both M. tb and host factors are urgently needed to improve the clinical management outcomes of MDR-TB. Host-directed therapies (HDT) could avert destructive tuberculous lung pathology, facilitate eradication of M. tb, improve survival and prevent long-term functional disability. In this review we (1) discuss the use of HDT for cancer and other infections, drawing parallels and the precedent they set for MDR-TB treatment, (2) highlight preclinical studies of pharmacological agents commonly used in clinical practice which have HDT potential, and (3) outline developments in cellular therapy to promote clinically beneficial immunomodulation to improve treatment outcomes in patients with pulmonary MDR-TB. The use of HDTs as adjuncts to MDR-TB therapy requires urgent evaluation.
| Type: | Article |
|---|---|
| Title: | Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1186/s12916-016-0635-1 |
| Publisher version: | http://dx.doi.org/10.1186/s12916-016-0635-1 |
| Language: | English |
| Additional information: | © 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Medicine, General & Internal, General & Internal Medicine, Tuberculosis, Multidrug Resistance, Host-Directed Therapies, Immunomodulatory Agents, Immune Response, Inflammation, Histone Deacetylase Inhibitors, Regulatory T-Cells, Community-Acquired Pneumonia, Reconstitution Inflammatory Syndrome, Active Pulmonary Tuberculosis, Extensively Drug-Resistant, Placebo-Controlled Trial, Population-Based Cohort, Prior Statin Use, Mycobacterium-Tuberculosis |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Infection and Immunity |
| URI: | https://discovery.ucl.ac.uk/id/eprint/1502806 |
Archive Staff Only
 |
View Item |
